Enzymology of the reduction of the novel fused pyrazine mono-N-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase

This publication has 32 references indexed in Scilit:

• Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)
  British Journal of Cancer, 1995
• Reduction of 3-amino-l,2,4-benzotriazine-l,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH: cytochrome P450 oxidoreductase
  Carcinogenesis: Integrative Cancer Research, 1994
• EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models
  European Journal Of Cancer, 1993
• Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent
  Cancer and Metastasis Reviews, 1993
• Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: Pharmacology and activity in vitro and in vivo
  International Journal of Radiation Oncology*Biology*Physics, 1992
• Synthesis and evaluation of .alpha.-[[(2-haloethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of .alpha.-[(1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogs which are radiosensitizers and bioreductively activated cytotoxins
  Journal of Medicinal Chemistry, 1990
• Structure-activity relationships for benzotriazine DI-N-oxides
  International Journal of Radiation Oncology*Biology*Physics, 1989
• Molecular mechanisms for the hypoxiadependent activation of 3-amino-1,2,4-benzotriazine-1, 4-dioxide (SR 4233)
  Biochemical Pharmacology, 1988
• SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
  International Journal of Radiation Oncology*Biology*Physics, 1986
• The role of mitomycin antibiotics in the chemotherapy of solid tumors
  Biochemical Pharmacology, 1986